tradingkey.logo

Transmedics Group Inc

TMDX
135.060USD
+5.460+4.21%
Close 02/06, 16:00ETQuotes delayed by 15 min
4.61BMarket Cap
49.90P/E TTM

Transmedics Group Inc

135.060
+5.460+4.21%

More Details of Transmedics Group Inc Company

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Inc Info

Ticker SymbolTMDX
Company nameTransmedics Group Inc
IPO dateMay 02, 2019
CEOHassanein (Waleed H)
Number of employees728
Security typeOrdinary Share
Fiscal year-endMay 02
Address200 Minuteman Road
CityANDOVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01810
Phone19785520900
Websitehttps://www.transmedics.com/
Ticker SymbolTMDX
IPO dateMay 02, 2019
CEOHassanein (Waleed H)

Company Executives of Transmedics Group Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-47529.00%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+2134.00%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-5640.00%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+2134.00%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+2134.00%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+2134.00%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-15653.00%
Mr. Anil Ranganath
Mr. Anil Ranganath
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Dr. Tamer I. Khayal, M.D.
Dr. Tamer I. Khayal, M.D.
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-47529.00%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+2134.00%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-5640.00%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+2134.00%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+2134.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
107.94M
75.67%
OCS Heart net revenue
30.59M
21.44%
OCS Lung net revenue
4.11M
2.88%
By RegionUSD
Name
Revenue
Proportion
United States
139.01M
97.46%
All other countries
3.63M
2.54%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
OCS Liver net revenue
107.94M
75.67%
OCS Heart net revenue
30.59M
21.44%
OCS Lung net revenue
4.11M
2.88%

Shareholding Stats

Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
Other
55.32%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
Other
55.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor
72.28%
Investment Advisor/Hedge Fund
23.64%
Hedge Fund
7.07%
Research Firm
4.62%
Individual Investor
2.95%
Bank and Trust
2.03%
Pension Fund
1.35%
Sovereign Wealth Fund
0.18%
Family Office
0.15%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
800
38.04M
111.30%
-5.53M
2025Q3
762
37.62M
110.09%
-8.17M
2025Q2
746
42.27M
124.01%
-2.30M
2025Q1
751
42.32M
125.08%
-2.32M
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.74M
13.86%
+9.44K
+0.20%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.60M
13.45%
-31.07K
-0.67%
Sep 30, 2025
The Vanguard Group, Inc.
3.60M
10.53%
+9.16K
+0.26%
Sep 30, 2025
State Street Investment Management (US)
1.28M
3.74%
-9.47K
-0.73%
Sep 30, 2025
Two Sigma Investments, LP
1.06M
3.1%
+366.05K
+52.85%
Sep 30, 2025
Nomura Investment Management Business Trust
906.27K
2.65%
-45.84K
-4.81%
Sep 30, 2025
Geode Capital Management, L.L.C.
813.57K
2.38%
+8.92K
+1.11%
Sep 30, 2025
Driehaus Capital Management, LLC
738.16K
2.16%
-115.88K
-13.57%
Sep 30, 2025
Hood River Capital Management LLC
678.44K
1.99%
-1.41K
-0.21%
Sep 30, 2025
Emerald Advisers LLC
626.03K
1.83%
-68.95K
-9.92%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X HealthTech ETF
4.75%
Clough Select Equity ETF
2.87%
Invesco S&P SmallCap Health Care ETF
2.75%
State Street SPDR S&P Health Care Equipment ETF
2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.47%
iShares S&P Small-Cap 600 Growth ETF
0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.58%
View more
Global X HealthTech ETF
Proportion4.75%
Clough Select Equity ETF
Proportion2.87%
Invesco S&P SmallCap Health Care ETF
Proportion2.75%
State Street SPDR S&P Health Care Equipment ETF
Proportion2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion1.47%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.58%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI